
## **Supplementary Material**

## Supplemental table I. Patients with major adverse cardiac events

	Culprit lesion related events	Non-culprit lesion related events	Indeterminat e events	Non-culprit lesion related and indeterminat e events combined	All events
Composite of major adverse cardiac events, n	11	27	18	45	56
Death from any cause, n	1	1	16	17	18
Definite cardiac or unexplained sudden death, n	1	1	6	7	8
Acute coronary syndrome, n	3	9	2	11	14
Myocardial infarction, n	2	3	2	5	7
Elective coronary revascularization, n	7	17	0	17	24
Composite of death or acute coronary syndrome, n	4	10	18	28	32


## Supplemental figure I. Patient inclusion



Patients were included in the current study analyses when the following criteria were met: 1. not participating in the IBIS-2 trial; 2. IVUS of a non-culprit coronary artery was performed; and 3. plasma samples were available for biomarker measurements. In patients who were additionally included at Erasmus MC (n=768), IVUS of a non-culprit coronary artery was performed in 581 patients (red shaded). In these patients, blood samples were available in 570 patients.

IBIS-2 indicates Integrated Biomarker and Imaging Study-2; IVUS, intravascular ultrasound; NIRS, near-infrared spectroscopy; n.a., not applicable.

## Supplemental figure II. Methodology for detection of lesion and reference segments



\*: all consecutive frames with more than 40% of plaque burden

MLA indicates minimal luminal area, REF, reference segments; ROI, region of interest.